Form 4: Exagen Inc. Director Kahn Scott D Acquires Stock Options
SEC Form 4 Filing
Director Kahn Scott D acquired stock options in Exagen Inc. on June 10, 2024.
Summary
- On June 10, 2024, Kahn Scott D, a director of Exagen Inc., acquired 15,000 stock options with an exercise price of $1.99.
- The options vest in 36 equal monthly installments over three years, starting July 10, 2024, contingent on continued service to the issuer.
- Following the transaction, Kahn Scott D directly owns 15,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. The acquisition of options could be seen as mildly positive, but it's a routine transaction.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Future Outlook
The vesting schedule of the options is contingent on the reporting person's continued service to the issuer.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency into insider transactions.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's success.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of the stock option transaction. |
| 07/10/2024 | Start date for the monthly vesting of the stock options. |
| 06/09/2034 | Expiration date of the stock options. |
| 06/14/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.